Diamyd Medical announces share capital and total number of shares as of January 29, 2010

As of January 29, 2010, the share capital in Diamyd Medical AB (publ.)(STO:DIAMB)(Pink Sheets:DMYDY) is 14 330 494 SEK. The total number of votes is 4 160 187 and the total number of shares is 28 660 988, divided among 1 437 876 shares of series A (1 vote) and 27 223 112 shares of series B (1/10 vote).

This change is due to the exercise of granted employee stock options in the stock option plan 2007/2010, approved by the Annual Meeting of Shareholders 2007, and in the stock option plan 2008/2011, approved by the Annual Meeting of Shareholders 2008, and to the executed division of shares (a split), meaning that each share has been divided into two shares of the same class, approved by the Annual Meeting of Shareholders on December 11, 2009.

Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd® for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company currently has three clinical-phase products.